Susan Hasty, Publisher
Table of Contents . . . October 18th, 2001
Non-Subscriber - Summaries OnlyRelated Areas: Other Issues in Gene Therapy Weekly | Other Publications
Leukemia - Quantitative Wilms Tumor Gene Useful For Disease Monitoring
Vaccination - Interleukin-2 Fusion Protein Enhances DNA Vaccine Effectiveness
Bacterial Meningitis - Recombinant Bordetella Boosts Neisseria Vaccine Development
Birth Defects - Treating Congenital Problems With Gene Therapy In Utero Believed Possible
HIV Resistance - Mutations Causing Partial CCR5 Dysfunction Still Confer Protection
Hepatocellular Carcinoma - Intratumoral Gene Therapy Delivery Best Approach In Primary Liver Cancer
Viral Vectors - Questions Surround Tumor Development After Gene Therapy In Mice
AIDS Therapies - Adefovir Has Limited Effect On Drug Resistance Risk
Appointments - Dr. Serge Braun Becomes Vice President Of Research At Transgene
Astrocytoma - Scientists Have Bred Accurate Animal Model Of Human Brain Tumor
Cancer Gene Therapy - Combination Approach Selectively Kills Pancreatic Cancer Cells
Cell Division - Researchers Build Diagram Of Cell Cycle Clock
Chemotherapy - AuraZyme Presents Progress Report On Cancer Drug Delivery System
Drug Development - IKK-2 Inhibitor Has Anti-Inflammatory/Anticancer Potential
Dyslipidemia - AVANT Gets Patent Protection For Intellectual Property Of Anticholesterol Agent
Familial Amyloid Polyneuropathy - Scientists Discover Novel Therapeutic Strategy
Functional Genomics - Scientists Make Case For Haplotype Map Of Human Genome; Identify Crohn Gene
Gene Transfer - Moving Gene In Plant Results In Increased Production Of Amino Acid
Inflammatory Myopathies - New Technology Can Confirm Muscle Disease Diagnosis
Patents - Introgen Gets Worldwide License For Anticancer Therapy
Therapy - Anticancer Agent Licensed To Antisoma's Targeted Apoptosis Program
Vectors - MediGene Expands License For Universal Application Of HSV Amplicon Technology
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.